Wijtvliet VPWM, Plaeke P, Abrams S, et al. - Whether donor‐derived cell‐free DNA (dd‐cfDNA) has worth as a non‐invasive biomarker in detecting kidney allograft rejection, was determined in this systematic review and meta‐analysis. Original research papers on dd‐cfDNA fractions in blood of kidney allograft recipients were searched in Pubmed, Web of Science, and the Cochrane Library between January 1994 and May 2020. Although there was heterogeneity among the examined studies, meta‐analysis revealed that patients with antibody‐mediated rejection (ABMR) had significantly higher median dd‐cfDNA fractions vs those without rejection or those with stable graft function. Overall, findings are indicative of the likely usefulness of dd‐cfDNA as a marker for ABMR, but probably not for T cell‐mediated rejection.